Related Experiment Video

Updated: May 20, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

Tankyrase 2 as a therapeutic target in non-small cell lung cancer: Implications for apoptosis and migration

Jing Yu1, Bo-Tao Xu2, Qiu Li1

  • 1Department of Respiratory Medicine, Zhuji people's Hospital, Zhuji 311800, Zhejiang Province, China.

World Journal of Clinical Oncology
|March 25, 2025
PubMed

Insights

Tankyrase 2 (TNKS2) drives non-small cell lung cancer (NSCLC) malignancy by inhibiting apoptosis and promoting cell migration. Targeting TNKS2 may offer new therapeutic strategies for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
  • Identifying novel molecular drivers and therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of tankyrase 2 (TNKS2) in the progression of non-small cell lung cancer (NSCLC).
  • To explore the underlying mechanisms by which TNKS2 contributes to NSCLC malignancy.

Main Methods:

  • Experiments were conducted using NSCLC cell lines.
  • Analysis focused on TNKS2's impact on apoptosis, cellular migration, and the β-catenin pathway.

Main Results:

  • Overexpression of TNKS2 was found to stabilize β-catenin.
  • This stabilization led to increased oncogenic gene expression and enhanced cellular migration.
  • TNKS2 activity was linked to inhibition of apoptosis.

Conclusions:

  • TNKS2 plays a pivotal role in NSCLC malignancy.
  • TNKS2 represents a potential therapeutic target and prognostic marker for NSCLC.
  • Further in vivo validation and clinical studies are warranted.
Keywords:
ApoptosisCell migrationMetastasisNon-small cell lung cancerTherapeutic target

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.8K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K